You are here

ASCO 2016

AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors

Forbes

Sun, 06/5/16 - 11:50 am

non-small cell lung cancer

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

Yahoo

Sun, 06/5/16 - 11:48 am

Juno Therapeutics

B-cell malignancies

Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting

Yahoo

Sat, 06/4/16 - 06:27 pm

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Yahoo

Sat, 06/4/16 - 06:19 pm

Kite Pharma rides CAR-T momentum into ASCO

BioPharma Dive

Fri, 06/3/16 - 09:46 pm

Immunotherapy At ASCO: The Cancer Research Institute On What To Watch

Forbes

Fri, 06/3/16 - 10:43 am

cancer immunotherapy

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

TheStreet.com

Fri, 06/3/16 - 09:49 am

triple negative breast cancer

What You Need to Know About the World's Biggest Cancer Conference

Fortune

Thu, 06/2/16 - 03:52 pm

Five Storylines To Watch At ASCO

Forbes

Tue, 05/31/16 - 11:14 am

PDL-1 inhibitors

3 Stories To Watch At The Year’s Biggest Cancer Conference

Investors.com

Mon, 05/30/16 - 06:34 pm

non-small cell lung cancer

Bristol-Myers Squibb

Here are 13 MA cancer biotechs hoping to make waves next month

Bizjournals.com

Fri, 05/20/16 - 11:36 am

Ariad Pharmaceuticals

Vertex Pharmaceuticals

Infinity Pharmaceuticals

Foundation Medicine

Cerulean Pharma

Merck, Bristol drugs show longer survival for deadly cancers

Yahoo/Reuters

Thu, 05/19/16 - 09:59 am

Bristol-Myers Squibb

cancer immunotherapy

Pages